CagriSema for Weight Loss: What the Evidence Shows
What human and animal studies show about CagriSema for weight loss, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 8
- with an outcome for weight loss, in our evidence file (PubMed search, 2 Oct 2026)
- Animal studies
- None found
- with an outcome for weight loss, in our evidence file (PubMed search, 2 Oct 2026)
- Studies we summarised
- 10
- with an outcome for weight loss
Evidence for weight loss
Each row is an outcome related to weight loss from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Body weight vs semaglutide alone | Body weight changed by -18·4% with CagriSema versus -11·9% with semaglutide alone at week 68 (difference -6·5 percentage points). | Human RCTn = 331 | The lancet. Diabetes & endocrinology 2026, PMID 42009015 |
| Body weight at week 40 | Body weight changed by -13·8% with CagriSema (2·4 mg each) versus -1·4% with placebo. | Human RCTn = 189 | The lancet. Diabetes & endocrinology 2026, PMID 42251860 |
| Body weight | CagriSema provided body weight reductions of 10-12%. | Human RCTn = 274 | Lancet 2026, PMID 42251856 |
| Reaching BMI and waist-to-height targets | 30.3% reached both BMI under 27 and waist-to-height ratio under 0.53 with CagriSema, versus 19.1% semaglutide, 9.0% cagrilintide and 3.3% placebo. | Human controlled trial | Diabetes, obesity & metabolism 2026, PMID 42503495 |
| Body weight at week 68 (coprimary) | Body weight changed by -20.4% with CagriSema versus -3.0% with placebo at week 68 (difference -17.3 percentage points). | Human RCTn = 3417 | The New England journal of medicine 2025, PMID 40544433 |
| Body weight at week 68 (primary) | Body weight changed by -13.7% with CagriSema versus -3.4% with placebo at week 68 (difference -10.4 percentage points). | Human RCTn = 1206 | The New England journal of medicine 2025, PMID 40544432 |
| Body weight at week 32 | Body weight changed by -15·6% with CagriSema, -5·1% with semaglutide and -8·1% with cagrilintide at week 32. | Human RCTn = 92 | Lancet 2023, PMID 37364590 |
| Body weight at week 20 (with semaglutide 2.4 mg) | Combined with semaglutide, body weight fell by 15·7% (cagrilintide 1·2 mg) and 17·1% (2·4 mg) versus 9·8% with pooled placebo at week 20. | Human RCTn = 96 | Lancet 2021, PMID 33894838 |
| Weight loss vs semaglutide | CagriSema produced a mean difference of -7.47% (-7.60 kg) greater weight loss than semaglutide. | Meta-analysisn = 3545 | Diabetes, obesity & metabolism 2026, PMID 41834765 |
| Weight, waist, blood pressure and HbA1c | Versus placebo, CagriSema reduced body weight by a mean difference of -5.98% (-4.68 kg) and waist circumference by -10.91 cm, with reductions in systolic blood pressure and HbA1c. | Meta-analysisn = 5425 | Annals of medicine and surgery 2026, PMID 42583410 |
CagriSema and weight loss are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our evidence scale.
How strong is it?
Strongest evidence:Human RCT evidence, 4 of 4The lancet. Diabetes & endocrinology 2026, PMID 42009015
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for weight loss
All peptides for weight loss, comparedCommon questions
Does CagriSema help with weight loss?
The strongest study we summarise for weight loss is human rct evidence, across 10 studies with an outcome for weight loss. A trial result is not an approval; see the legal status.
Is CagriSema approved for weight loss?
No. CagriSema is not FDA approved for any use, including weight loss.
What is the best peptide for weight loss?
There is no single answer. Our weight loss overview compares each candidate by evidence grade and legal status rather than by popularity.
More on CagriSema
Sources
- 1Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.The lancet. Diabetes & endocrinology · 2026PMID 42009015Accessed 2 Oct 2026
- 2Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026PMID 42251860Accessed 2 Oct 2026
- 3Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet (London, England) · 2026PMID 42251856Accessed 2 Oct 2026
- 4Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.Diabetes, obesity & metabolism · 2026PMID 42503495Accessed 2 Oct 2026
- 5Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
- 6Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
- 7Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 2 Oct 2026
- 8Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
- 9Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.Diabetes, obesity & metabolism · 2026PMID 41834765Accessed 2 Oct 2026
- 10Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
Found an error? Report a correction.